OBJECTIVES: To investigate whether CD146 gene expression could provide useful information to predict early recurrence after nephrectomy. METHODS: This study included 84 patients with clear cell renal cell carcinoma (cRCC), and 44 subjects without tumor were used as controls. Quantitative RT-PCR was used to measure the CD146 gene expression. RESULTS: The mean value of CD146 expression in patients with metastatic cRCC (0.0438±0.0024) was significantly higher than in those with localized cRCC (0.0374±0.0012, P=0.018) or in controls (0.0344±0.0010, P=0.001). Of patients with localized cRCC, those with recurrence had a significantly higher CD146 expression than those without recurrence (P=0.029). The univariate analysis showed that CD146 was associated with early recurrence. The recurrence-free survival curve indicated that patients with a high CD146 expression had a significantly higher recurrence rate than those with a low CD146 expression (P=0.018). CONCLUSIONS: CD146 gene expression can be useful for predicting early recurrence and stratifying the patients into risk groups for possible adjuvant treatment.
OBJECTIVES: To investigate whether CD146 gene expression could provide useful information to predict early recurrence after nephrectomy. METHODS: This study included 84 patients with clear cell renal cell carcinoma (cRCC), and 44 subjects without tumor were used as controls. Quantitative RT-PCR was used to measure the CD146 gene expression. RESULTS: The mean value of CD146 expression in patients with metastatic cRCC (0.0438±0.0024) was significantly higher than in those with localized cRCC (0.0374±0.0012, P=0.018) or in controls (0.0344±0.0010, P=0.001). Of patients with localized cRCC, those with recurrence had a significantly higher CD146 expression than those without recurrence (P=0.029). The univariate analysis showed that CD146 was associated with early recurrence. The recurrence-free survival curve indicated that patients with a high CD146 expression had a significantly higher recurrence rate than those with a low CD146 expression (P=0.018). CONCLUSIONS:CD146 gene expression can be useful for predicting early recurrence and stratifying the patients into risk groups for possible adjuvant treatment.
Authors: N Bardin; F Anfosso; J M Massé; E Cramer; F Sabatier; A Le Bivic; J Sampol; F Dignat-George Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: Tobias Klatte; David B Seligson; Jeffrey LaRochelle; Brian Shuch; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz F Kabbinavar; Allan J Pantuck; Arie S Belldegrun Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-24 Impact factor: 4.254
Authors: Gwladys Zabouo; Anne-Marie Imbert; Jocelyne Jacquemier; Pascal Finetti; Thomas Moreau; Benjamin Esterni; Daniel Birnbaum; François Bertucci; Christian Chabannon Journal: Breast Cancer Res Date: 2009-01-05 Impact factor: 6.466
Authors: J Stalin; M Nollet; P Garigue; S Fernandez; L Vivancos; A Essaadi; A Muller; R Bachelier; A Foucault-Bertaud; L Fugazza; A S Leroyer; N Bardin; B Guillet; F Dignat-George; M Blot-Chabaud Journal: Oncogene Date: 2016-04-11 Impact factor: 9.867
Authors: Joseph W Wragg; Jonathan P Finnity; Jane A Anderson; Henry J M Ferguson; Emilio Porfiri; Rupesh I Bhatt; Paul G Murray; Victoria L Heath; Roy Bicknell Journal: Cancer Res Date: 2016-02-26 Impact factor: 12.701
Authors: Francisca O Gbormittah; Ling Y Lee; KyOnese Taylor; William S Hancock; Othon Iliopoulos Journal: J Proteome Res Date: 2014-09-10 Impact factor: 4.466